Cilostazol

SKU: orb1310589

Description

Cilostazol (OPC 21) is a selective phosphodiesterase 3 (PDE3) inhibitor. It is widely used in research to study vasodilation, inhibition of platelet aggregation, and cellular proliferation in both in vitro and in vivo experimental models.

Research Area

Cell Biology, Metabolism Research, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 73963-72-1
• MW: 369.5
• Purity: >98%
• Formula: C₂₀H₂₇N₅O₂
• SMILES: C(CCCOC=1C=C2C(=CC1)NC(=O)CC2)C=3N(N=NN3)C4CCCCC4
• Target: PDE (Phosphodiesterase)
• Solubility: Soluble in DMSO (up to 20 mg/ml).

Bioactivity

• Target IC50:
  PDE3:0.2 μM
• In Vivo:
  Cilostazol induces relaxation of vascular smooth muscle and causes vasodilation. It inhibits the expression of monocyte chemotactic protein-1 (MCP-1) induced by cytokines. Additionally, Cilostazol reduces plasma triglycerides and increases high-density lipoprotein (HDL) levels. The vasodilatory and antithrombotic effects of Cilostazol are primarily due to the inhibition of phosphodiesterase 3 (PDE3) and the subsequent elevation of intracellular cyclic adenosine monophosphate (cAMP) levels. It also inhibits platelet aggregation and adenosine uptake.
  Read more...

Storage & Handling

• Storage: RT
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Cilostazol, Autophagy, cardiovascular, fibrogenesis, hepatic, Inhibitor, injury, late, inhibit, PDE3, OPC21, OPC-21, OPC13013, OPC-13013, OPC 21, OPC 13013, phosphodiesterase, Phosphodiesterase (PDE)

Compound Identifiers

PubChem CID

2754